Showing 1,881 - 1,900 results of 23,507 for search '"globalized"', query time: 0.10s Refine Results
  1. 1881

    DeepGlioSeg: advanced glioma MRI data segmentation with integrated local-global representation architecture by Ruipeng Li, Yuehui Liao, Yueqi Huang, Xiaofei Ma, Guohua Zhao, Yanbin Wang, Chen Song

    Published 2025-02-01
    “…First, a CTPC (CNN-Transformer Parallel Combination) module leverages parallel branches of CNN and Transformer networks to fuse local and global features of glioma images, enhancing feature representation. …”
    Get full text
    Article
  2. 1882

    Global Research Hotspots in Venous Thromboembolism Anticoagulation: A Knowledge-Map Analysis from 2012 to 2021 by Jia Wang, Yang-Xi Liu, Yi-Dan Yan, Li Liu, Chi Zhang, Mang-Mang Pan, Hou-Wen Lin, Zhi-Chun Gu

    Published 2023-01-01
    “…Therefore, our study aimed to analyze the global status, hotspots, and trends of anticoagulant therapy for VTE. …”
    Get full text
    Article
  3. 1883
  4. 1884

    Global-Local Self-Attention-Based Long Short-Term Memory with Optimization Algorithm for Speaker Identification by Pravin Marotrao Ghate, Bhagvat D. Jadhav, Shriram Sadashiv Kulkarni, Pravin Balaso Chopade, Prabhakar N. Kota

    Published 2025-01-01
    “…To mitigate the limitations mentioned above, this research proposes Global Local Self-Attention (GLSA) based Long Short-Term Memory (LSTM) with Exponential Neighborhood – Grey Wolf Optimization (EN-GWO) method for effective speaker identification using TIMIT and VoxCeleb 1 datasets. …”
    Get full text
    Article
  5. 1885

    MADONNA’S FOUR-DECADE INFLUENCE: BRAND STRATEGY AND GLOBAL IMPACT OF THE CELEBRATION TOUR RIO DE JANEIRO by Pedro BELTRÁN CUERVO, Cecilia VALLEJOS PARÁS

    Published 2024-12-01
    “…This research explores the evolution of global perceptions around her brand following her 2024 Celebration Tour, culminating in a record-breaking closing concert in Rio de Janeiro attended by 1.6 million people. …”
    Get full text
    Article
  6. 1886
  7. 1887

    The role of host plants, land cover and bioclimate in predicting the invasiveness of Aromia bungii on a global scale by Enrico Ruzzier, Seunghyun Lee, Pietro Tirozzi, Valerio Orioli, Andrea Di Giulio, Olivia Dondina, Luciano Bani

    Published 2025-01-01
    “…Abstract Aromia bungii is an invasive Cerambycidae of major concern at the global scale because of the damage caused to Rosaceae. …”
    Get full text
    Article
  8. 1888
  9. 1889
  10. 1890
  11. 1891

    Dynamics of breast imaging research: A global scoping review and Sino-Australian comparison case study. by Seyedamir Tavakoli Taba, Patrick C Brennan, Sarah Lewis

    Published 2019-01-01
    “…This study presents a quantitative analysis of global breast imaging research over the last eight decades. …”
    Get full text
    Article
  12. 1892
  13. 1893
  14. 1894
  15. 1895

    Complex Interplay of Eastern Bloc SMEs Trade Credit Determinants: Changes due to the Global Financial Crisis by Tamara Teplova, Tatiana Sokolova, Kristina Galenskaya, Mariya Gubareva

    Published 2022-01-01
    “…We investigate whether the determinants of small and medium enterprises’ (SMEs) trade credits taken for purchasing fixed assets suffered substantial changes due to the global financial crisis (GFC). The geographical focus of this paper covers 18 former Eastern bloc countries. …”
    Get full text
    Article
  16. 1896

    Abrocitinib monotherapy in Investigator’s Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life by Andrew Blauvelt, Mark Boguniewicz, Patrick M. Brunner, Paula C. Luna, Pinaki Biswas, Marco DiBonaventura, Saleem A. Farooqui, Ricardo Rojo, Michael C. Cameron

    Published 2022-07-01
    “…Background Abrocitinib, a once-daily, oral Janus kinase 1 selective inhibitor, was shown to be an effective treatment for moderate-to-severe atopic dermatitis in phase 2 b/3 monotherapy trials.Methods These analyses included data for Investigator’s Global Assessment responder (clear [0] or almost clear [1] with ≥2-grade improvement) and nonresponder patients with moderate-to-severe atopic dermatitis who received abrocitinib (200 mg or 100 mg) or placebo in three abrocitinib monotherapy trials (phase 2 b, NCT02780167; two phase 3, NCT03349060/JADE MONO-1 and NCT03575871/JADE MONO-2). …”
    Get full text
    Article
  17. 1897
  18. 1898
  19. 1899
  20. 1900